Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. - Wikidata - wikimedia - TriplyDB

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

http://www.wikidata.org/entity/Q44428863

about

Aripiprazole alone or in combination for acute mania Aripiprazole alone or in combination for acute mania The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study.Risk assessment of isolated aripiprazole exposures and toxicities: a retrospective study.Assessing QT interval prolongation and its associated risks with antipsychotics.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.Genetics of antipsychotic treatment emergent weight gain in schizophrenia.Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163).The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in Korea Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole.Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics.Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review.Effects of aripiprazole on subjective and physiological responses to alcohol.Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control.Risk of osteoporosis and fracture incidence in patients on antipsychotic medication.Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder.The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study Aripiprazole for late-life schizophrenia Efficacy and tolerability of aripiprazole: a 26-week switching study from oral antipsychotics.A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting.Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.Meta-analysis methods for risk differences.Antipsychotics for delirium in the general hospital setting in consecutive 2453 inpatients: a prospective observational study.Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.Atypical experience: a case series of pediatric aripiprazole exposures.Aripiprazole (abilify) overdose in a child.Aripiprazole: pharmacology, efficacy, safety and tolerability.Patterns of initiation of second generation antipsychotics for bipolar disorder: a month-by-month analysis of provider behavior.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression Almost all antipsychotics result in weight gain: a meta-analysis.New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study

P2860

Q24201765-71DAA64E-FAFB-4095-995A-8A190C6101A1 Q24247531-A5F35FFA-FD47-4D0D-80C8-EDAC65D64102 Q30475523-FE967802-CD88-4C18-AD4A-8D9CD72484CB Q30654033-4D7ECC03-3F86-41F5-8953-3F22C40BC87F Q33157585-D9692019-DBFB-4744-BF05-86420AA13D06 Q33160123-D96D8C03-68E7-40A7-8361-435D4B020F32 Q33223628-C4BB79A3-7059-4937-AFAD-22CE77495048 Q33235110-B07D8B86-41D5-4785-B52E-51AC744A5922 Q33257886-83AA8C43-2924-4E68-8552-9E73D4C04960 Q33518314-0F1691C2-C628-4C7C-9CF2-651E21CE751A Q33587032-8E199160-631C-43C2-9F37-3257CC9234E4 Q33619940-EFB36FF3-A548-480C-8C2A-2421304FBDCE Q33662847-8A31F01A-5F84-4CE8-B532-9AC97F93D028 Q33755676-E03DB2AD-263B-4D7E-B4DD-AB54A6C03125 Q33799660-BA91E33A-E351-4893-A82C-7624349B69CD Q33811763-CB0807C9-30E3-4DE9-B734-185631A0703E Q33819964-4C421880-CE77-4715-8275-92ACFA377444 Q33903464-AC183042-1A6C-451D-A941-A49EF38FC00C Q34009852-D0B4AA51-8D60-493C-BE87-FDD7D36132BF Q34013720-52B5B525-1C0F-4B11-A7A4-B0FE984F7CF2 Q34026011-777D4FD5-B379-432D-B275-83E40C214836 Q34027230-E3AE7152-4B95-4006-AB07-9C1B4347CF8A Q34110039-44F3D589-904E-46B4-9071-6C3E4EEE4BBE Q34121832-A1B1142B-9D72-4B58-9848-76C8B55FD6B4 Q34165051-C2D84C9D-CB5D-43B3-BD12-ECFDCB40C54E Q34174609-E84904A1-A197-4A60-9F28-E8E8274C0089 Q34338202-0387D4B6-CB2D-48E1-97AE-9ABB67A558F3 Q34365330-F49660B0-7D4A-46E1-BFC8-3F249D4F2F52 Q34497222-547C2432-1467-4062-A573-659340A4D4AA Q34544811-6A6CE962-738E-43B6-98DD-A723D0D964F0 Q34557775-126552C4-6990-42A3-852B-A63C192B71E4 Q34557780-63394C6F-9706-4424-86BE-5E24E798D3A4 Q34558285-E22AEEAD-DCCA-46B0-94BB-7ECF736BCF14 Q34636572-944368CF-F090-420E-B68B-E55DE31A1967 Q34640811-A70EF902-8C9A-4F17-8B27-F3B7C5E4299E Q34642676-61AB4006-6441-4183-86F8-EA4EBE13669E Q34661499-AE60F86A-D3EB-4382-B78F-F43647DCF22C Q34772251-26B951EA-9B3D-4751-819A-757AF299056B Q34925151-34D7D0A0-BA20-4FCB-AC6A-EEB44A5D7582 Q35191252-425E17C5-3721-4806-A3F0-9ABD88DC8A23

P2860

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

http://www.wikidata.org/entity/Q44428863

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Aripiprazole in the treatment ...... rm, placebo-controlled trials.

@en

Aripiprazole in the treatment ...... rm, placebo-controlled trials.

@nl

type

label

Aripiprazole in the treatment ...... rm, placebo-controlled trials.

@en

Aripiprazole in the treatment ...... rm, placebo-controlled trials.

@nl

prefLabel

Aripiprazole in the treatment ...... rm, placebo-controlled trials.

@en

Aripiprazole in the treatment ...... rm, placebo-controlled trials.

@nl

P1433

Q44428863-983BE447-D8B1-41BA-A379-00E73BD9D652

P1476

Q44428863-7323F23B-1973-4D3B-8DEC-D4BC0F360F09

P2093

Q44428863-0F499CB2-4D92-4D87-AB9A-1262C3A2FA02

Q44428863-2B5B8A3F-E223-4BB6-9312-C07C8E45D64B

Q44428863-3E2F8EDC-6F2B-4896-A4B5-9C1B4DDF8AE3

Q44428863-3FA0E92D-22CC-4666-8EA6-52D3F6E8C9F2

Q44428863-4F91B857-A04A-4094-86CE-37F59F85070E

Q44428863-6E1C72B9-F57F-4112-845A-12D55057C422

Q44428863-A80EA527-869B-4AA5-B9A6-2A5C367ACD08

Q44428863-AEC0908F-5D92-441B-8AC5-7479D8D0FCFC

Q44428863-C4709CEA-A7B1-4A9C-BBE7-6A5F2AD25DBB

P304

Q44428863-BD81BFB5-984A-46BE-AD48-5125E1C8406E

P31

Q44428863-3FB8FA71-F3FF-46AC-A19F-B125CFFB81D4

Q44428863-ef9aa380-c2a3-4447-b907-e6b99d41e7c2

P356

Q44428863-A5ABE853-4E49-4398-A4BF-4DAF0A3220FC

P407

Q44428863-812EAB2F-0051-4866-92B6-25C079FA6B15

P433

Q44428863-ED4597C6-C8A7-472A-BBB8-FB24E1CBDD07

P478

Q44428863-58E50691-F2DA-4957-B081-96E1D9368991

P577

Q44428863-B7D71E51-EC5C-427C-BFD5-39223417DA72

P5875

Q44428863-7B4BC106-2D9D-4A24-AEA8-CFB82D67FEB4

P698

Q44428863-FC1D8B29-D93D-4D16-AEED-7E83884FB0D4

P921

Q44428863-764C3613-9577-4EBE-A133-BB1D7A18D6BB

Q44428863-85BD1164-88E1-4687-89AF-AF3B4048E7F1

P356

S0920-9964(03)00050-1

P1433

Schizophrenia Research

P1476

Aripiprazole in the treatment ...... rm, placebo-controlled trials.

@en

P2093

Allan Z Safferman

http://www.w3.org/2001/XMLSchema#string

Anutosh Saha

http://www.w3.org/2001/XMLSchema#string

Elyse Stock

http://www.w3.org/2001/XMLSchema#string

Mirza Ali

http://www.w3.org/2001/XMLSchema#string

Robert D McQuade

http://www.w3.org/2001/XMLSchema#string

Ronald Marcus

http://www.w3.org/2001/XMLSchema#string

Stephen Kaplita

http://www.w3.org/2001/XMLSchema#string

Stephen R Marder

http://www.w3.org/2001/XMLSchema#string

Taro Iwamoto

http://www.w3.org/2001/XMLSchema#string

P304

123-136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0920-9964(03)00050-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

2-3

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10775145

http://www.w3.org/2001/XMLSchema#string

P698

12729864

http://www.w3.org/2001/XMLSchema#string

P921